Mouse Anti-Omicron Nucleocapsid Antibody, IgG1 (MOF032922W1)

Cat: MOF032922W1
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

  • Product Details


Host speciesMouse
Species ReactivitySARS-CoV-2 Omicron (B.1.1.529) Nucleocapsid Protein
SARS-CoV-2 Nucleocapsid Protein
SARS-CoV-2 Alpha(B.1.1.7) Nucleocapsid(R203K, G204R) Protein
SARS-CoV-2 Alpha(B.1.1.7) Nucleocapsid(I292T) Protein
SARS-CoV-2 Alpha(B.1.1.7) Nucleocapsid(D3L, R203K, G204R, S235F) Protein
SARS-CoV-2 Alpha(B.1.1.7) Nucleocapsid(D3L, S235F) Protein
SARS-CoV-2 Alpha(B.1.1.7/ B.1.237) Nucleocapsid(S194L) Protein
SARS-CoV-2 Alpha/beta(B.1.1.7/ B.1.351/ A.2.2) Nucleocapsid(P13L) Protein
SARS-CoV-2 Beta(B.1.351/B.1.351.2/b.1.351.3/B.1.427/B.1.429) Nucleocapsid (T205I) Protein
SARS-CoV-2 Gamma(P.1/ P.1.1/ P.1.2) Nucleocapsid (P80R) Protein
SARS-CoV-2 Eta(B.1.525) Nucleocapsid (A12G, T205I) Protein
SARS-CoV-2 (B.1.617) Nucleocapsid (D377Y) Protein
SARS-CoV-2 (B.1.617) Nucleocapsid (R203M, D377Y) Protein
SARS-CoV-2 Delta(B.1.617.2) Nucleocapsid (D63G, R203M, D377Y) Protein
SARS-CoV-2 (B.1.617.3) Nucleocapsid (P67S, R203M, D377Y) Protein
SpecificityRecognize Omicron Nucleocapsid Protein.
ImmunogenSARS-CoV Nucleoprotein / NP Protein
FormatLiquid or Lyophilized
Regulatory StatusFor Research Use Only. Not For Clinical Use.
ShippingGel Pack
StorageStore at 4°C: short-term (1-2weeks)
Store at -20°C: long-term and future use
Purity> 95% was determined by SDS-PAGE
PurificationProtein A

Application Information

ApplicationWB, ELISA, IHC-P, FC
Application NotesWB: 1:1000-1:10000
ELISA: 1:1000-1:2000
IHC-P: 1:1000-1:5000
FC: 1:25-1:100
The optimal dilution should be determined by the end user.


IntroductionOmicron multiplies in the bronchi (lung airways) about 70 times faster than the Delta variant, but there is evidence that it is not as severe as previous strains, especially compared to the Delta variant. Omicron may not penetrate deep lung tissue. Omicron infections had a 91% lower fatality rate and a 51% lower risk of hospitalization than the delta variant. However, when reinfection was excluded, the estimated difference in the risk inherent in hospitalization was greatly reduced to 0-30%. Overall, the extremely high transmission rate, combined with its ability to evade dual vaccination and the body's immune system, means that the total number of patients requiring hospitalization at any given time remains a concern.
For Research Use Only | Not For Clinical Use.
Online Inquiry